Optinate (risedronate) is a new bisphosphate registered for the prevention and treatment of postmenopausal osteoporosis including corticosteroid-induced osteoporosis.
There are two treatment regimes: Optinate 5 mg once a day and Optinate Septimum 35 mg once a week. There does not seem to be any clinically relevant differences between Optinate and Fosamax.
The price of Optinate is lower than that of Fosamax (prices of 2004), but considerably higher than the price of Didronate.
Optinate is not granted general reimbursement, but single reimbursement can be applied for.
Optinate 5 mg and Optinate Septimum 35 mg were marketed on May 24, 2004.
Last modified: May 30th 2004